

Neuralstem, Inc.  
Form 8-K  
March 09, 2012

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 9, 2012 (March 7, 2012)**

**Neuralstem, Inc.**

**(Exact name of registrant as specified in Charter)**

Delaware

000-1357459

**52-2007292**

**(State or other jurisdiction of** (Commission File No.) (IRS Employee Identification No.)

**incorporation or organization)**

**9700 Great Seneca Highway, Rockville, Maryland 20850**

**(Address of Principal Executive Offices)**

**(301) 366-4841**

**(Issuer Telephone number)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

On March 7, 2012, Neuralstem, Inc. (“Company”) updated the progress of its ongoing Phase I human clinical trial of the Company’s spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) at Emory University in Atlanta, Georgia, by announcing that the second patient to receive stem cells in the cervical (upper back) region of the spine was dosed on February 29th. A copy of the press release is attached to this report as Exhibit 99.01.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information set forth in this form 8-K and its exhibits shall not be deemed an admission as to the materiality of any information within this report.

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit Number** Description

99.01 Press Release Dated March 7, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr  
I. Richard Garr  
Chief Executive Officer

Dated: March 9, 2012